There are some highly promising diabetes treatments entering the market that investors should know about.
News & Analysis: Eli Lilly and Company
Value investing is all about being willing to buy solid companies when the market throws a sale.
Wall Street hasn't been impressed by the makers of Humira and Trulicity lately, but their long-term prospects look stronger.
Investors weren't impressed with the drugmaker's Q3 report. Should bargain hunters take advantage of this recent weakness in its shares?
LLY earnings call for the period ending September 30, 2019.
The big drugmaker seemingly did what it needed to do in Q3. Except for one thing.
These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
GLP-1 drugs keep getting easier to take.
AbbVie and Eli Lilly have both stumbled this year. Which of these top pharma stocks is better positioned for a rebound?
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.